Key Takeaways BSX advances in PFA with FARAPULSE showing strong growth and favorable trial results.BSX saw U.S. double-digit FARAPULSE growth aided by the adoption of OPAL HDx and integrated NAV technology.BSX gained FDA label expansion and advanced PFA tools like FARAPOINT to broaden AF treatment.Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific (BSX) holds a leadin ...